Ramez N Eskander

Trials

Studies that name Ramez N Eskander as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:55 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT03914612 · Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  National Cancer Institute (NCI) · active not recruiting · Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma · principal investigator
• Ph2
  NCT03348631 · Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

  National Cancer Institute (NCI) · active not recruiting · Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• NRG Oncology Network Group Operations Center
  U10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026
  Named on NCT03914612, NCT03348631